MIRA INFORM REPORT

 

 

Report Date :

27.05.2013

 

IDENTIFICATION DETAILS

 

Name :

PHARMACHEMIE B.V.

 

 

Registered Office :

Swensweg 5 2031GA Haarlem

 

 

Country :

Netherlands

 

 

Date of Incorporation :

23.12.1959

 

 

Com. Reg. No.:

34096191

 

 

Legal Form :

Private Company

 

 

Line of Business :

Manufacture of pharmaceutical preparations

 

 

No. of Employees :

560

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Good

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Netherlands

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

NETHERLANDS -  ECONOMIC OVERVIEW

 

The Dutch economy is the sixth-largest economy in the euro-zone and is noted for its stable industrial relations, moderate unemployment and inflation, a sizable trade surplus, and an important role as a European transportation hub. Industrial activity is predominantly in food processing, chemicals, petroleum refining, and electrical machinery. A highly mechanized agricultural sector employs only 2% of the labor force but provides large surpluses for the food-processing industry and for exports. The Netherlands, along with 11 of its EU partners, began circulating the euro currency on 1 January 2002. After 26 years of uninterrupted economic growth, the Dutch economy - highly dependent on an international financial sector and international trade - contracted by 3.5% in 2009 as a result of the global financial crisis. The Dutch financial sector suffered, due in part to the high exposure of some Dutch banks to U.S. mortgage-backed securities. In 2008, the government nationalized two banks and injected billions of dollars of capital into other financial institutions, to prevent further deterioration of a crucial sector. The government also sought to boost the domestic economy by accelerating infrastructure programs, offering corporate tax breaks for employers to retain workers, and expanding export credit facilities. The stimulus programs and bank bailouts, however, resulted in a government budget deficit of 5.3% of GDP in 2010 that contrasted sharply with a surplus of 0.7% in 2008. The government of Prime Minister Mark RUTTE began implementing fiscal consolidation measures in early 2011, mainly reductions in expenditures, which resulted in an improved budget deficit in 2011. In 2012 tax revenues dropped nearly 9%, GDP contracted, and the budget deficit deteriorated. Although jobless claims continued to grow, the unemployment rate remained relatively low at 6.8 percent.

Source : CIA

 

CONTACTINFORMATION    

 

Company name

PHARMACHEMIE B.V.

Tradename

Pharmachemie B.V.

 

Teva Pharmachemie

 

Teva Pharmachemie Operations

Address

Swensweg 5

 

2031GA Haarlem

 

Netherlands

Mail address

Postbus 552

 

2003RN Haarlem

 

Netherlands

Telephone number

08000228400 / 0235147147

Telefax number

0235147192

Mobile phone

0653233114

E-mail address

pch.legal@tevapharmachemie.com

Website

www.tevapharmachemie.com

VAT number / RSIN

001012940

 

 

COMPANY INFORMATION

 

Handelsregisternummer 34016881

Registered in                             Chamber of commerce Amsterdam

 

Act of foundation                        23-12-1959

Date of constitution                    15-03-1944

Continuation date                       25-04-1972

Last change in statutes              07-01-2005

 

Legal form                                 Private Company

 

Place of constitution                   Haarlem

 

Capital                                      EUR

Issued capital                            EUR 354.150

Paid up capital                           EUR 354.150

 

NACE-code                               Manufacture of pharmaceutical preparations (2442)

SBI-code                                   Manufacture of pharmaceutical preparations (212)

Manufacture of pharmaceutical preparations (2120)

Manufacture of pharmaceutical products, no raw (212001)

Wholesale of pharmaceutical goods (46461)

Other specialised business services (7490)

 

Formal objective                         The import and export, the wholesale, manufacturing, and doing manufacture of pharmaceutical products, raw materials and products and the acquisition, provision and operating licenses, patents, patents, trademarks and other forms of industrial property owned The incorporate, to participate in managing, advising, checking, working with, the conduct of the management and on the provision of services to other vennnootschappen and companies, as well as finance companies and other companies

 

Employees

Total: 560

 

 

Employees according to CoC

Chamber of commerce: 560

 

 

Bookyear

2013

2012

2011

Number

560

565

565

Change

-0,88%

0,00%

0,00%

 

 

COMPANY STRUCTURE

 

Shareholder                               Pharmachemie Holding B.V.

Swensweg 5

2031GA HAARLEM

Netherlands

KvK: 30142776

Active since:                              19-03-1998

Percentage:                               100.00%

 

Ultimate parent company            Teva Pharmaceutical Industries

990005394938

 

Holding company                       Pharmachemie Holding B.V.

Swensweg 5

2031GA HAARLEM

KvK: 30142776

Subsidiary Cephalon B.V.

Swensweg 5

2031GA HAARLEM

KvK:     17169815

 

Teva Netherlands B.V.

Swensweg 5

2031GA HAARLEM

KvK: 34096191

 

Ivax Farma B.V.

Swensweg 5

2031GA HAARLEM

KvK: 34193015

Ratiopharm B.V.

Swensweg 5

2031GA HAARLEM

KvK: 39058803

Affiliated companies                   PCH Real estate B.V.

Swensweg 5

2031GA HAARLEM

KvK: 30091675

 

Farmaver B.V.

Swensweg 5

2031GA HAARLEM

KvK: 34088047

 

B.V. Pharbita

Swensweg 5

2031GA HAARLEM

KvK: 35009579

 

Liability declaration                    Pharmachemie Holding B.V. (30142776)

Swensweg 5

2031GA HAARLEM

 

Bank

ABN Amro Bank NV

 

Account number: 43.27.24.478

 

ING Bank NV

 

Account number: 188985

 

ING Bank NV

 

Account number: 6494361

 

ABN Amro Bank NV

 

Account number: 48.62.11.401

 

Real estate                                Group-property owned

 

 

MANAGEMENT

 

Management                             Teva Pharmaceuticals Europe B.V.

Computerweg 10

3542DR UTRECHT

Netherlands

KvK: 30110625

Authorization: Jointly authorized

Position: Manager

Date appointed: 03-10-2006

 

E.G.W.H. Loof

Emile Gerardus Wilhelmus Hendr

Authorization: Jointly authorized

Position: Manager

Date appointed: 14-04-2000

Date of birth: 09-06-1949

 

H.C. Diekema

Hendrik Cornelis

Authorization: Limited authorization (max: € 5.000)

Position: Proxy

Date appointed: 01-07-2010

Date of birth: 06-10-1963

 

M.A. Ince - Groenhof

Mirjam Anselma

Authorization: Limited authorization

Position: Proxy

Date appointed: 03-07-2012

Date of birth: 16-06-1965

 

J.M. Maaskant

Johanna Maria

Authorization: Limited authorization

Position: Proxy

Date appointed: 03-07-2012

Date of birth: 02-06-1963

 

M.T. Prinsen - Fris

Maria Theresia

Authorization: Limited authorization (max: € 5.000)

Position: Proxy

Date appointed: 01-07-2010

Date of birth: 13-02-1967

 

J.W. van Wijk

Jan Willem

Authorization: Limited authorization

Position: Proxy

Date appointed: 03-07-2012

Date of birth: 17-10-1962

 

 

PAYMENT INFORMATION

 

Payment experiences                 Payments are regular

Payments                                 Based on multiple payment experiences up to € 50.000

Quarter: 3 2012: 68 Average days

Quarter: 4 2012: 66 Average days

Quarter: 1 2013: 62 Average days

Quarter: 2 2013: 58 Average days

 

 

invoices

current quarter

2013 Q1

2012 Q4

2012 Q3

Total

228

100%

542.501

593.555

599.054

586.919

Within terms

55

37,7%

204.633

169.398

151.248

139.149

Delayed 0 - 30

146

56,5%

306.439

390.519

408.004

419.662

Delayed 31 - 60

12

4,1%

22.367

33.638

8.410

25.228

Delayed 61 - 90

5

0,8%

4.539

 

31.392

 

Delayed 91 - 120

9

0,8%

4.523

 

 

1.152

Delayed 120+ days

1

0,0%

 

 

 

1.728

 

 

FINANCIAL INFORMATION 

 

Auditor

PricewaterhouseCoopers

Auditor's report

According to the auditor, the annual account gives a faithful description of the size and composition of the company.

 

Annual accounts

There is no financial information published

Tendency

Upward

Profitability

Positive

Solvency

Sufficient

Liquidity

Sufficient

Currency

Euro

 

 

History

           

Liability statements

Per 13-03-2008 filed a declaration of liability by Pharmachemie Holding B.V..

Per 13-03-2008 filed a withdrawal of declaration of liability by Teva Pharmaceuticals

Europe B.V..

Management

Per 03-07-2012 is Proxy Denise van Schooten out of office.

Per 03-07-2012 is Proxy Mirjam Anselma Ince-Groenhof appointed.

Per 03-07-2012 is Proxy Jan Willem van Wijk appointed.

Per 03-07-2012 is Proxy Johanna Maria Maaskant appointed.

Per 01-07-2010 is Proxy Denise van Schooten appointed.

Per 01-07-2010 is Proxy Maria Theresia Prinsen-Fris appointed.

Per 01-07-2010 is Proxy Hendrik Cornelis Diekema appointed.

 

 

Company structure

 

·         Teva Pharmaceutical Industries (990005394938)

o        Teva Pharmaceuticals Europe B.V. (30110625)

UTRECHT

Subsidiary

§         Teva Pharma B.V. (30099369)

Utrecht

Subsidiary (100%)

§         Pharmachemie Holding B.V. (30142776)

HAARLEM

Subsidiary

§         PCH Real estate B.V. (30091675)

HAARLEM

Subsidiary

§         Pharmachemie B.V. (34016881) Haarlem

Subsidiary

§         Cephalon B.V. (17169815)

HAARLEM

Subsidiary

§         Teva Netherlands B.V. (34096191)

HAARLEM

Subsidiary

§         Ivax Farma B.V. (34193015)

HAARLEM

Subsidiary

§         Ratiopharm B.V. (39058803)

HAARLEM

Subsidiary

§         Holland Pharmaceutical Supply B.V. (28036413)

HAARLEM

Subsidiary

§         ratiopharm netherlands B.V. (30063629)

HAARLEM

Subsidiary

§         Pharmethica B.V. (39062775)

HAARLEM

Subsidiary

§         Farmaver B.V. (34088047)

HAARLEM

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.55.61

UK Pound

1

Rs.83.98

Euro

1

Rs.71.94

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.